DHAP方案治疗复发或难治性非霍奇金淋巴瘤疗效观察  

Clinical study of DHAP regimen for patients with relapsed or refractory in the treatment of advanced non-Hodgkin's lymphoma

作　　者：赵晓华[1] 尹勇灵[1] 

机构地区：[1]内蒙古医科大学附属人民医院血液科,内蒙古呼和浩特010020

出　　处：《疾病监测与控制》2012年第8期472-473,共2页Journal of Diseases Monitor and Control

摘　　要：目的为了观察DHAP方案治疗复发难治性非霍奇金淋巴瘤(non-Hodgkin's lymphoma,NHL)的临床疗效和不良反应。方法选择复发难治性NHL患者16例,采用DHAP方案化疗:DDP 85mg/m2,静脉滴入,d1;Ara-c2g/m2,静脉滴注,d2,每1次/12h;DXM 40mg/d,静脉推注,d1～d4。21～28d为1周期,共完成2～6个周期。结果 16例患者CR6例(37.5%),PR5例(31.2%),SD3例(18.8%),PD2例(12.5%),总有效率为68.7%(11/16)。主要毒副反应为血细胞下降和消化道反应,均可耐受。结论初步研究结果显示,DHAP方案是治疗复发难治性NHL的有效解救化疗方案,缓解率高,不良反应可以耐受,值得临床进一步观察。Objective This study was to observe the efficacy and toxicity of DH AP regimen for the patient with relapse or refractory advanced non-Hodgkin＇ s Lymphoma. Methods Sixteen patients were treated by DH AP egimen：Cisplatin 85mg / m^2, infused every on day 1, arabinoside cytarabine 2 g / m^2, infused every 12 h for 2 doses, dayl, dexamcthasone 40 mg o n days 1 to 4. All patients received 2 to 6 cycles of chemotherapy. Results All the patients were heated by DH AP regimen. The response rate for the whole group was 68.7 （11/16）, including 6 complete responses symptoms （CR） （37.5%） and 5 partial responses （PR） （31.2%）. Main toxicities were myelosuppression and gastrointestinal. Conclusion Other toxicities were mild. DH AP regimen is effective for t he patient s with relapsed or refractory advanced non-Hodgkin＇ s Lymphoma.

关 键 词：非霍奇金淋巴瘤 DHAP方案 临床研究 

分 类 号：R733.4[医药卫生—肿瘤]